A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma

Part 1 (5-Fluorouracil [5-FU] plus cisplatin [FP] and paclitaxel plus cisplatin [TP] Safety Run-in): Number of Participants With Dose Limiting Toxicities (DLTs), Part 1 (FP and TP Safety Run-in): Number of Participants With Adverse Events (AEs), Part 1 (FP and TP Safety Run-in): Number of Participants who Discontinued Study Treatment Due to an AE, Part 2 (Main Study): Overall Survival (OS) in all Participants